EGFR and non-small cell lung carcinoma: Our results showed that, for EGFRm-positive NSCLC patients who received EGFR-TKI treatment, real-world clinical outcomes (median OS approximately 35 months, median TTF approximately 12 months) were comparable with those reported in other countries (20, 21, 23, 25, 26).